News Related to Idiopathic Hypersomnia

Related coverage linked through entity extraction aliases.

Alkermes reports additional phase 2 alixorexton data in narcolepsy type 1

Apr 19, 2026

Additional phase 2 data showed alixorexton sustained improvements in disease severity, cognition and fatigue in narcolepsy type 1 through weeks 12-13. The oral orexin 2 receptor agonist was generally well tolerated, with no serious treatment-emergent adverse events reported.

FDA Grants Priority Review to Takeda's Oveporexton for Narcolepsy Type 1

May 03, 2025

The FDA accepted Takeda's NDA for oveporexton (TAK-861), an oral orexin receptor 2 agonist for narcolepsy type 1, and granted Priority Review with a PDUFA goal date in Q3 2026. The drug could become the first approved orexin agonist.